Antiarrhythmic effect of newly synthesized compound 44Bu on model of aconitine-induced arrhythmia - Compared to lidocaine
Antiarrhythmic effect of newly synthesized compound 44Bu on model of aconitine-induced arrhythmia - Compared to lidocaine
复制标题
DOI：
10.1016/j.ejphar.2007.07.044
复制
发表时间：
2007-12-01
影响因子：
5
通讯作者：
Suchy, Pavel
中科院分区：
文献类型：
--
作者：
Bartosova, Ladislava;Novak, Filip;Suchy, Pavel
在乌头碱诱发的心律失常模型上测试了新开发的化合物 44Bu（我们药学院合成的原始化合物）的抗心律失常作用，并与利多卡因的效果进行了比较。两种测试物质都作为治疗剂或预防剂施用。 44Bu 非常有效地将心室颤动的发生率从治疗性给药的 94% 降低到 8%，通过预防性给药降低到 0%。 44Bu使总死亡率在治疗性给药的情况下从100%显着降低至25%，在预防性给药的情况下降低至0%。相反，利多卡因的治疗性和预防性给药之间没有任何显着差异。治疗性给药时心室颤动的发生率从 94% 下降到 50%，预防性给药利多卡因时室颤的发生率从 94% 下降到 67%，总死亡率分别从 100% 显着降低到 63% 和 67%。我们得出结论，44Bu 化合物是抑制乌头碱诱发的心律失常的高效药物。与利多卡因相比，44Bu 的抗心律失常作用明显更明显，特别是在预防性给药的情况下。 (C) 2007 Elsevier B.V. 保留所有权利。
The antiarrhythmic action of the newly developed compound 44Bu (an original compound that was synthesized at our Faculty of Pharmacy) was tested on a model of aconitine-induced arrhythmia and compared with the effect of lidocaine. Both tested substances were administered either as therapeutic or prophylactic agents. 44Bu was highly effective in reducing the occurrence of ventricular fibrillation from 94% to 8% by therapeutic administration, and to 0% by prophylactic administration. The overall mortality rate was significantly reduced by 44Bu from 100% to 25% in the case of therapeutic administration, and to 0% in the case of prophylactic administration. In contrast, there was not any significant difference between therapeutic and prophylactic administration of lidocaine. The occurrence of ventricular fibrillation dropped from 94% to 50% with therapeutic administration, and to 67% with prophylactic administration of lidocaine, The overall mortality rate was significantly reduced from 100% to 63% and to 67%, respectively. We conclude that the 44Bu compound is a highly effective agent in suppressing aconitine-induced arrhythmias. The antiarrhythmic effect of 44Bu was significantly more evident in comparison with lidocaine, particularly in the case of its prophylactic administration. (C) 2007 Elsevier B.V. All rights reserved.